The quarter cleared the main earnings bar. Adjusted FFO was $0.46 per share, two cents above the published consensus of roughly $0.44. GAAP EPS was $0.08 versus $0.05 a year earlier, but the more relevant REIT measure was essentially flat year over year at the adjusted-FFO level.
| Metric | Q2 2026 | Comparison | Read |
|---|---|---|---|
| Adjusted FFO per share | $0.46 | ~$0.44 consensus | Beat |
| Total revenue | $771.6M | $694.3M in Q2 2025 | Higher, largely reflecting senior housing consolidation |
| Adjusted FFO per share | $0.46 | $0.46 in Q2 2025 | Flat year over year |
| FY 2026 adjusted FFO guidance | $1.73–$1.77 | $1.71–$1.75 previously | Midpoint +$0.02 |
| FY 2026 same-store cash NOI growth | 0%–1.5% | (1)%–1% previously | Range improved by 75 bps |
Management raised the outlook rather than merely reaffirming it. The full-year adjusted-FFO range moved to $1.73–$1.77 from $1.71–$1.75, while same-store cash NOI guidance shifted from a possible decline to a 0%–1.5% gain. That is the clearest incremental signal in the filing and supports a modestly better-than-expected operating picture. (Guidance)
The underlying portfolio is mixed, not uniformly improving. Q2 same-store adjusted NOI reached $335.4 million versus $329.4 million a year earlier, but outpatient medical same-store adjusted NOI was $189.1 million versus $184.5 million, while lab was $114.2 million versus $118.0 million. Senior housing improved to $32.1 million from $26.9 million, making that segment a major offset to lab weakness. (Segment results — Total Portfolio; Segment results — Outpatient Medical, Lab, and Senior Housing)
Capital allocation was the stronger strategic takeaway. Healthpeak generated approximately $1.75 billion of year-to-date proceeds, including roughly $1.025 billion from selling a 49% interest in the Brookfield outpatient medical joint venture, then used proceeds to repay $650 million of senior notes and approximately $375 million of commercial paper. The balance sheet ended June with $1.63 billion of cash and 37.8% financial leverage, although the Brookfield transaction and debt actions were largely previously disclosed rather than fresh surprises. (Capital allocation; Balance Sheet / Debt metrics)
Net: a narrow beat with a better outlook, tempered by uneven same-store performance. The consensus comparison favors a positive read, but the quarter itself did not show broad organic acceleration: adjusted FFO was flat year over year, outpatient growth was modest, and lab remained under pressure. The guidance increase and balance-sheet strengthening are what lift the filing above merely in line. (Financial Highlights; Guidance)
Read the original 8-K on SEC EDGAR ↗